Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12259606 | 0.88 | JAK2 (0.40) | LMNAEPHX2NPY5RCNR2GAA | |
| SCHEMBL2394467 | 0.81 | EPHX2 (0.49) | LMNAEPHX2 | |
| SCHEMBL2392198 | 0.80 | EPHX2 (0.41) | LMNAEPHX2FAAHTSHR | |
| SCHEMBL1710318 | 0.79 | PKM (0.43) | LMNAEPHX2GAA | |
| SCHEMBL2392681 | 0.78 | MAPT (0.41) | LMNANPY5RCNR2SMN1; SMN2ADRA2A | |
| SCHEMBL2391747 | 0.78 | EPHX2 (0.43) | LMNAEPHX2 | |
| SCHEMBL2395689 | 0.78 | EPHX2 (0.43) | LMNAEPHX2 | |
| SCHEMBL12259605 | 0.77 | EPHX2 (0.45) | LMNAEPHX2 | |
| SCHEMBL1710700 | 0.76 | KMT2A (0.40) | LMNAEPHX2GAA | |
| SCHEMBL12310154 | 0.75 | EPHX2 (0.43) | LMNAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012980-B2 | Isoquinolinone derivatives | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | SDHA, NQO1, CYP3A5 | LMNA 1339/4885EPHX2 3078/4885NPY5R 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.